Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,110,407 shares of the biopharmaceutical company’s stock after buying an additional 174,482 shares during the quarter. Wellington Management Group LLP owned 1.58% of Alnylam Pharmaceuticals worth $635,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in ALNY. Daiwa Securities Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp increased its holdings in shares of Alnylam Pharmaceuticals by 20.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 40 shares in the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC raised its position in shares of Alnylam Pharmaceuticals by 3.3% in the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 40 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 0.2%

NASDAQ ALNY opened at $237.10 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The company has a market capitalization of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. The company has a fifty day moving average of $262.62 and a 200 day moving average of $293.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.51) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALNY. Sanford C. Bernstein reissued an “outperform” rating and set a $376.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Bank of America lowered their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a research report on Monday, August 3rd. HC Wainwright reduced their target price on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, Citigroup lowered their price target on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Insider Buying and Selling

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.